Comparison · NCT02153528-deaths
Standard TB Treatment vs Double Rimfampicin: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Standard TB Treatment vs Double Rimfampicin: deaths from any cause. Trial comparisons, record NCT02153528-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02153528-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0489 | 0.0307 | 0.0768 | wilson | |
| Risk in group 2 | 0.034 | 0.0196 | 0.0585 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0149 | -0.0156 | 0.0463 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.44 | 0.697 | 2.96 | log | |
| Odds ratio, group 1 over group 2 | 1.46 | 0.686 | 3.1 | log | |
| Number needed to harm, for one more death from any cause on Standard TB Treatment than on Double Rimfampicin | 67.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Standard TB Treatment | Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease~Standard TB treatment: Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease | 17 | 348 | EG000 |
| Group 2 | Double Rimfampicin | 2HREZ/4HR Cat. 1, modified by using double dose rifampicin throughout~double rimfampicin: Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained | 12 | 353 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Serious adverse events are recorded until end of treatment (up to 8 months). No (non-serious) adverse events are recorded in this trial.
Source ClinicalTrials.gov
Trial
- Title
- Optimization of the TB Treatment Regimen Cascade
- NCT number
- NCT02153528
- Phases
- PHASE3
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- double rimfampicin, Standard TB treatment
- Lead sponsor
- Damien Foundation
- Results first posted
- 2020-02-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02153528?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02153528-deaths